Skip to content

Study · Animal study (in vivo) · mouse · 2008

3 results

Differential neuroprotective effects of carnosine, anserine, and N-acetyl carnosine against permanent focal ischemia.

Min J, Senut MC, Rajanikant K, Greenberg E, Bandagi R, Zemke D, Mousa A, Kassab M, Farooq MU, Gupta R, Majid A

Journal of neuroscience research1 Oct 2008Cited by 54 (Europe PMC)

PMID18543335 (opens in a new tab)PMCIDPMC2805719 (opens in a new tab)DOI10.1002/jnr.21744 (opens in a new tab)PepBankPUB-18543335
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with permanent focal cerebral ischemia, carnosine significantly reduced infarct volume versus vehicle, with benefits maintained for 7 days.

    In plain wordsIn mice, carnosine reduced infarct volume compared with vehicle, with benefits maintained for 7 days.

    Peptide
    L-carnosine
    Outcome
    DecreaseInfarct volume
    Study

    mousen: not reported in source

    permanent focal cerebral ischemia
    Comparator
    vehicle-treated mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    We demonstrated that treatment with carnosine, but not its analogues, was able to significantly reduce infarct volume and improve neurological function compared with those in vehicle-treated mice. These beneficial effects were maintained for 7 days post-pMCAO.
    1 context sentence
    Summary · context
    Permanent focal cerebral ischemia was induced by occlusion of the middle cerebral artery (pMCAO). Mice were subsequently randomly assigned to receive an intraperitoneal injection of vehicle (0.9% saline), carnosine, N-acetyl carnosine, anserine, bestatin alone, or bestatin with carnosine.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with permanent focal cerebral ischemia, carnosine significantly improved neurological function versus vehicle, with benefits maintained for 7 days.

    In plain wordsIn mice, carnosine improved neurological function compared with vehicle, with benefits maintained for 7 days.

    Peptide
    L-carnosine
    Outcome
    IncreaseNeurological function
    Study

    mousen: not reported in source

    permanent focal cerebral ischemia
    Comparator
    vehicle-treated mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    We demonstrated that treatment with carnosine, but not its analogues, was able to significantly reduce infarct volume and improve neurological function compared with those in vehicle-treated mice. These beneficial effects were maintained for 7 days post-pMCAO.
    1 context sentence
    Summary · context
    Permanent focal cerebral ischemia was induced by occlusion of the middle cerebral artery (pMCAO). Mice were subsequently randomly assigned to receive an intraperitoneal injection of vehicle (0.9% saline), carnosine, N-acetyl carnosine, anserine, bestatin alone, or bestatin with carnosine.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with permanent focal cerebral ischemia, adding carnosine prevented the increase in ischemic lesion severity seen with bestatin.

    In plain wordsIn mice, adding carnosine prevented the increase in ischemic lesion severity seen with bestatin alone.

    Peptide
    L-carnosine
    Outcome
    DecreaseIschemic lesion severity with bestatin
    Study

    mousen: not reported in source

    permanent focal cerebral ischemia
    Comparator
    bestatin alone
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, compared with the vehicle-treated group, bestatin-treated mice displayed an increase in the severity of ischemic lesion, which was prevented by the addition of carnosine.
    1 context sentence
    Summary · context
    Permanent focal cerebral ischemia was induced by occlusion of the middle cerebral artery (pMCAO). Mice were subsequently randomly assigned to receive an intraperitoneal injection of vehicle (0.9% saline), carnosine, N-acetyl carnosine, anserine, bestatin alone, or bestatin with carnosine.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.